To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic
treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy
variable of SREs (Skeletal Related Events) and to assess the safety in nasopharyngeal
patients with bone metastases randomized to receive either zometa 4 mg or anti-neoplastic
treatment alone.